Serum lipids and the progression of nephropathy in type 1 diabetes.
暂无分享,去创建一个
Merlin C. Thomas | M. Taskinen | C. Forsblom | M. Rönnback | P. Groop | Merlin C Thomas | M. Cooper | M. Rosengård-Bärlund | G. Viberti | Stephen G. Thomas | V. Mills | M. Thomas | M. Cooper
[1] H. Parving,et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy , 1992, Diabetologia.
[2] Merlin C. Thomas,et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.
[3] J. Armitage,et al. Cardiovascular outcomes among participants with diabetes in the recent large statin trials , 2004, Current opinion in lipidology.
[4] B. Nordestgaard,et al. Transendothelial lipoprotein exchange and microalbuminuria. , 2004, Cardiovascular research.
[5] M. Taskinen,et al. LDL subclasses in IDDM patients: relation to diabetic nephropathy , 1994, Diabetologia.
[6] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[7] V. Kamanna. Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease. , 2002, Histology and histopathology.
[8] P. Bennett,et al. Risk factors for renal failure: The WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.
[9] L. Fried,et al. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. , 2001, Journal of diabetes and its complications.
[10] C. Tsalamandris,et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] M. Maekawa,et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. , 2001, Clinical chemistry.
[12] H. Parving,et al. Progression of diabetic nephropathy. , 2001, Kidney international.
[13] M. Cooper,et al. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. , 2000, Diabetes & metabolism.
[14] I. Meredith,et al. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. , 2000, Journal of the American College of Cardiology.
[15] J. Hokanson,et al. Erratum: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes (Diabetes Case (1999) 22 (1165-1170)) , 1999 .
[16] J. Hokanson,et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. , 1999, Diabetes care.
[17] M. Adachi,et al. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. , 1998, Atherosclerosis.
[18] G. Watts,et al. Apolipoprotein B independently predicts progression of very-low-level albuminuria in insulin-dependent diabetes mellitus. , 1996, Metabolism: clinical and experimental.
[19] M. Taskinen,et al. Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease , 1996, Diabetes.
[20] R. Bucala. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] L. V. Van Gaal,et al. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. , 1995, Diabetes research and clinical practice.
[22] M. Taskinen,et al. Lipoprotein(a) in Type 1 Diabetic Patients with Renal Disease , 1994, Diabetic medicine : a journal of the British Diabetic Association.
[23] M. Taskinen,et al. Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy , 1994, Diabetes Care.
[24] A. Krolewski,et al. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. , 1994, Kidney international. Supplement.
[25] L. Kuller,et al. Predictors of Microalbuminuria in Individuals with IDDM: Pittsburgh Epidemiology of Diabetes Complications Study , 1993, Diabetes Care.
[26] O. Wiklund,et al. Cholesterol: a renal risk factor in diabetic nephropathy? , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] M. Taskinen,et al. Growth, serum lipoproteins and apoproteins in infants with congenital nephrosis. , 1992, Clinical nephrology.
[28] S. Wilens,et al. Glomerular lipidosis in intercapillary glomerulosclerosis. , 1951, Annals of internal medicine.